OMCAZIO approved for administration without regard to food, removing strict fasting requirements for cabozantinib patients SAN JOSE, CA AND TAIPEI, TW / September 11, 2026 / Handa Pharmaceuticals, Inc. (“Handa” or the “Company”) (TSE:6620) announced that the U.S. Food and Drug Administration (“FDA”) has granted final approval to OMCAZIO™ (cabozantinib) capsules, the laurylsulfate salt formulation...Read More